Aurobindo Pharma expecting first biosimilar approval in US in 12-18 months
Aurobindo Pharma is expecting to receive an approval for its first biosimilar product in the US in the next 12-18 months, while in Europe, the company hopes a green signal by 2022. Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, … Read more
